Patents by Inventor Volker Seibert
Volker Seibert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240102044Abstract: Provided are TCRs (e.g., TCRs that bind to NY-ESO-1), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.Type: ApplicationFiled: March 27, 2023Publication date: March 28, 2024Applicant: MiNK Therapeutics, Inc.Inventors: Marc van Dijk, Volker Seibert, Cornelia Anne Mundt, Arthur Andrew Hurwitz, Mark Adrian Exley, Benjamin Jacob Wolf, Daniel Leventhal, Sébastien Lalevée, Reed Masakayan
-
Publication number: 20240076232Abstract: Chemically toughened glass articles are provided that include a first compressive stress region extending from a first surface, a second compressive stress region extending from a second surface, and a chamfer structure at an edge, which connects the first and second surfaces. The first compressive stress region has a first compressive stress of 100 to 2000 MPa and a first 60% depth (F60D). The second compressive stress region has a second compressive stress of from 100 to 2000 MPa and a second 60% depth (S60D). The chamfered structure has a first ratio of average chamfer height (Havg) to a total chamfer height variation (TCHV) that is at least 250 ?m2.Type: ApplicationFiled: November 6, 2023Publication date: March 7, 2024Applicants: SCHOTT AG, SCHOTT Glass Technologies (Suzhou) Co. Ltd.Inventors: Wei Xiao, Ning Da, Feng He, Volker Seibert
-
Patent number: 11898165Abstract: Provided herein are engineered host cells suitable for expression of functional T cell receptors (TCR) and methods of using these cells to identify TCRs that specifically bind to a desired peptide-major histocompatibility complex (MHC) complex.Type: GrantFiled: September 9, 2016Date of Patent: February 13, 2024Assignee: MiNK Therapeutics, Inc.Inventors: Marc Van Dijk, Volker Seibert, Robert Benjamin Stein
-
Patent number: 11897962Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.Type: GrantFiled: August 21, 2020Date of Patent: February 13, 2024Assignees: AGENUS INC., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Volker Seibert, Olivier Léger, Marc Van Dijk, Taha Merghoub, David Schaer, Gerd Ritter, Takemasa Tsuji
-
Publication number: 20240034671Abstract: An element of an inorganic brittle material is provided having two opposed sides and a circumferential edge. The element has at least three sections that include a first section and two second sections. The second sections adjoin the first section so that the first section is between the second sections. The first section has an arrangement of openings and interconnectors so that the first section has a higher flexibility than the second sections. The arrangement of openings has at least one opening shaped as a fold with two limbs that intersect to form a vertex.Type: ApplicationFiled: July 28, 2023Publication date: February 1, 2024Applicants: SCHOTT AG, SCHOTT Glass Technologies (Suzhou) Co. Ltd.Inventors: Markus Heiss-Chouquet, Wei Xiao, Volker Seibert, Vanessa Glässer, Sebastian Leugner, Fabian Wagner, Feng He, Julia Weisshuhn
-
Publication number: 20230406946Abstract: The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.Type: ApplicationFiled: August 22, 2022Publication date: December 21, 2023Inventors: Nicholas S. WILSON, Jeremy D. WAIGHT, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Ekaterina V. BREOUS-NYSTROM, Volker SEIBERT, Takemasa TSUJI, Olivier LÉGER, Dennis J. UNDERWOOD, Marc VAN DIJK
-
Publication number: 20230399413Abstract: The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.Type: ApplicationFiled: August 22, 2022Publication date: December 14, 2023Inventors: Nicholas S. WILSON, Jeremy D. WAIGHT, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Ekaterina V. BREOUS-NYSTROM, Volker SEIBERT, Takemasa TSUJI, Olivier LÉGER, Dennis J. UNDERWOOD, Marc VAN DIJK
-
Publication number: 20230167186Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.Type: ApplicationFiled: September 8, 2022Publication date: June 1, 2023Inventors: Marc VAN DIJK, Ekaterina V. BREOUS-NYSTROM, Volker SEIBERT, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Hao TANG, David A. SAVITSKY, Jeremy WAIGHT, Nicholas S. WILSON
-
Publication number: 20230108348Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.Type: ApplicationFiled: September 8, 2022Publication date: April 6, 2023Inventors: Marc VAN DIJK, Ekaterina V. BREOUS-NYSTROM, Volker SEIBERT, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Hao TANG, David A. SAVITSKY, Jeremy WAIGHT, Nicholas S. WILSON
-
Patent number: 11613764Abstract: Provided are TCRs (e.g., TCRs that bind to NY-ESO-1), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.Type: GrantFiled: July 15, 2019Date of Patent: March 28, 2023Assignee: MiNK Therapeutics, Inc.Inventors: Marc van Dijk, Volker Seibert, Cornelia Anne Mundt, Arthur Andrew Hurwitz, Mark Adrian Exley, Benjamin Jacob Wolf, Daniel Leventhal, Sébastien Lalevée, Reed Masakayan
-
Publication number: 20230039577Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.Type: ApplicationFiled: June 22, 2022Publication date: February 9, 2023Inventors: Ana M. GONZALEZ, Nicholas S. Wilson, Dennis J. Underwood, Volker Seibert, Olivier Léger, Marc Van Dijk, Roberta Zappasodi, Taha Merghoub, Jedd David Wolchok, David Schaer, Gerd Ritter, Takemasa Tsuji
-
Patent number: 11472883Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.Type: GrantFiled: March 3, 2020Date of Patent: October 18, 2022Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Marc Van Dijk, Ekaterina V. Breous-Nystrom, Volker Seibert, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Hao Tang, David A. Savitsky, Jeremy Waight, Nicholas S. Wilson
-
Patent number: 11447557Abstract: The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.Type: GrantFiled: December 2, 2016Date of Patent: September 20, 2022Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Nicholas S. Wilson, Jeremy D. Waight, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Ekaterina V. Breous-Nystrom, Volker Seibert, Takemasa Tsuji, Olivier Léger, Dennis J. Underwood, Marc Van Dijk
-
Patent number: 11401335Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.Type: GrantFiled: January 15, 2020Date of Patent: August 2, 2022Assignees: AGENUS INC., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Ana M. Gonzalez, Nicholas S. Wilson, Dennis J. Underwood, Volker Seibert, Olivier Léger, Marc Van Dijk, Roberta Zappasodi, Taha Merghoub, Jedd David Wolchok, David Schaer, Gerd Ritter, Takemasa Tsuji
-
Publication number: 20220204382Abstract: The present disclosure relates to a thin glass for an optical component that includes a first side with a first surface and a second side opposite the first side with a second surface. The thin glass has a three-dimensional shape with at least one target curvature and a thickness of less than 700 ?m. On at least one first measurement area of 3×3 mm2 of the first surface, all surface structure components in a wavelength range of 0.1 mm to 1 mm have an arithmetical mean height Sa of below 30 nm, below 20 nm, below 10 nm, or below 8 nm. On the first measurement area, all surface structure components in a wavelength range from 0.1 mm to 1 mm can have an arithmetical mean height Sa of between 1 nm and 30 nm, between 3 nm and 20 nm, or between 6 nm and 10 nm. The values for the arithmetical mean height refer to a measurement by means of white light interferometry, with a bandpass filtering of 0.1 mm to 1 mm, i.e. with a bandpass filtering for viewing surface structure components in wavelength ranges from 0.Type: ApplicationFiled: March 18, 2022Publication date: June 30, 2022Applicant: SCHOTT AGInventors: Michael Meister, Katharina Alt, Volker Seibert, Ulrich Lange, Stephan Corvers
-
Publication number: 20220098316Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.Type: ApplicationFiled: September 1, 2021Publication date: March 31, 2022Inventors: Marc VAN DIJK, Ekaterina V. Breous-Nystrom, Volker Seibert, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Hao Tang, David A. Savitsky, Jeremy Waight, Nicholas S. Wilson
-
Publication number: 20220002185Abstract: An element of an inorganic brittle material having two opposed sides and a circumferential edge includes at least three sections. The at least three sections include a first section and two second sections, the second sections adjoining the first section so that the first section is arranged between the second sections. The first section includes an arrangement of openings forming passages from one side to an opposed side of the element so that the first section has a higher flexibility than the second sections.Type: ApplicationFiled: July 6, 2021Publication date: January 6, 2022Applicant: Schott AGInventors: Andreas Ortner, Julia Weißhuhn, Fabian Wagner, Markus Heiß-Chouquet, Volker Seibert, Feng He, Vanessa Gläßer, Ning Da, Wei Xiao
-
Patent number: 11181453Abstract: A method for testing the strength of a sheet-like element having two opposite faces and made of hard brittle material under tensile stress is provided. The method includes passing each of the faces of the element over a roller and thereby bending the element so that each of the faces is subjected to a first tensile stress in a portion in which the opposite face is in contact with a surface of the roller; exerting a second tensile force on the element in the direction of advancement so that both faces are subjected to the second tensile stress of at least 2 MPa so that the first and second tensile stresses add up to define a resultant tensile stress; and monitoring the element and determining whether the element has a defined breaking strength equal to the resultant tensile stress or whether the element breaks under the resultant tensile stress.Type: GrantFiled: January 13, 2020Date of Patent: November 23, 2021Assignee: SCHOTT AGInventors: Martin Lotze, Thomas Roßmeier, Clemens Ottermann, Volker Seibert
-
Patent number: 11155496Abstract: A method and an apparatus for stabilizing the position of a sheet-like element made of hard brittle material during transportation thereof along a transport path is provided in which the element is guided through a roller chicane having three rollers.Type: GrantFiled: September 9, 2016Date of Patent: October 26, 2021Assignee: SCHOTT AGInventors: Martin Lotze, Thomas Roßmeier, Clemens Ottermann, Volker Seibert
-
Publication number: 20210324097Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or diminish, deactivate, or suppress OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., diminishes, deactivates, or suppresses OX40 activity.Type: ApplicationFiled: March 4, 2021Publication date: October 21, 2021Inventors: Nicholas S. WILSON, Jeremy D. WAIGHT, Ekaterina V. BREOUS-NYSTROM, Volker SEIBERT, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Marc VAN DIJK